Press "Enter" to skip to content

New patent for Merck Sharp drug STEGLUJAN

1
Copyright © DrugPatentWatch. Originally published at New patent for Merck Sharp drug STEGLUJAN

Annual Drug Patent Expirations for STEGLUJAN
Annual Drug Patent Expirations for STEGLUJAN

Steglujan is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from one supplier. There are five patents protecting this drug.

STEGLUJAN drug price trends.

Drug patent litigation for STEGLUJAN.

This drug has one hundred and ninety-three patent family members in fifty-four countries.

The generic ingredient in STEGLUJAN is ertugliflozin; sitagliptin phosphate. One supplier is listed for this compound. Additional details are available on the ertugliflozin; sitagliptin phosphate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Merck Sharp drug STEGLUJAN

Comments are closed.

Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

Do NOT follow this link or you will be banned from the site!